View Filing Data

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2009	Dec. 31, 2008
Current assets
Cash and cash equivalents	$ 0	$ 0
Receivables, less allowance for doubtful accounts of $11,504 and $11,629 at December 31, 2009 and 2008, respectively	151,113	158,649
Inventory	51,256	45,227
Short term deferred taxes	12,913	0
Prepaid expenses and other current assets	3,999	2,766
Total current assets	219,281	206,642
Property and equipment, net	15,454	14,748
Long term deferred taxes	26,793	0
Other non-current assets	1,194	1,069
Goodwill	24,498	24,498
Total assets	287,220	246,957
Current liabilities
Line of credit	30,389	50,411
Accounts payable	74,535	76,936
Claims payable	4,068	5,230
Amounts due to plan sponsors	4,938	5,646
Accrued expenses and other current liabilities	14,273	9,575
Total current liabilities	128,203	147,798
Deferred taxes	0	533
Income taxes payable	2,437	2,764
Other non-current liabilities	787	325
Total liabilities	131,427	151,420
Stockholders' equity
Preferred stock, $.0001 par value; 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $.0001 par value; 75,000,000 shares authorized; shares issued: 42,766,478 and 41,622,629, respectively; shares outstanding; 39,675,865 and 38,691,356, respectively	4	4
Treasury stock, shares at cost: 2,647,613 and 2,624,186, respectively	(10,367)	(10,288)
Additional paid-in capital	254,677	248,441
Accumulated deficit	(88,521)	(142,620)
Total stockholders' equity	155,793	95,537
Total liabilities and stockholders' equity	$ 287,220	$ 246,957

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Dec. 31, 2009
Notes to Financial Statements [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"NOTE#160;2#160;#8212;#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Consolidation/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Use of Estimates/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates./font/divbr / div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Receivables/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Receivables include amounts due from certain third party payors and patient co-payments for pharmacies owned by the Company, amount s due from Plan Sponsors under the Company#8217;s PBM agreements, amounts due from pharmaceutical manufacturers for rebates, and service fees resulting from the distribution of certain drugs through retail pharmacies./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Allowance for Doubtful Accounts/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Allowances for doubtful accounts are based on estimates of losses related to customer receivable balances. The procedu re for estimating the allowance for doubtful accounts requires significant judgment and assumptions. The risk of collection varies based upon the product, the payor (commercial health insurance, government, and physician), the patient#8217;s ability to pay the amounts not reimbursed by the payor and the point of distribution (retail, national mail). The Company estimates the allowance for doubtful accounts based upon a variety of factors including the age of the outstanding receivables and the historical experience of collections, adjusting for current economic conditions and, in certain cases, evaluating specific customer accounts for risk of loss. The Company periodically reviews the estimation process and makes changes to the estimates as necessary. When it is deemed that a customer account is uncollectible, that balance is written off against the existing allowance./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div s tyle="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Allowance for Contractual Discounts/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company is reimbursed for the medications and services it sells by Plan Sponsors. Revenues and related accounts receivable are recorded net of payor contractual discounts to reflect the estimated net billable amounts for the products and services delivered. The Company estimates the allowance for contractual discounts, based on historical experience and in certain cases on a customer-specific basis, given its interpretation of the contract terms or a pplicable regulations. However, the reimbursement rates are often subject to interpretation that could result in payments that differ from estimates. Additionally, updated regulations and contract negotiations occur frequently, necessitating the continual review and assessment of the estimation process./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Inventory/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Inventory is recorded at the lower of cost or market. Cost is determined using the first-in, first-out method. Inventory consists principally of purchased prescription drugs for the Company#8217;s traditional mail and specialty distribution operations. Included in inventory is a reserve for expired inventory./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Property and Equipment/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Property and equipment is stated at cost less accumulated depreciation and amortization. Dep reciation is calculated using the straight-line method over the estimated useful lives of assets. The estimated useful lives of the Company#8217;s assets are as follows:/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div align="center" table cellpadding="0" cellspacing="0" width="85%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr td valign="top" width="77%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"Asset/font/font/div /td td valign="top" width="5%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEI GHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"Useful Life/font/font/div /td /trtr td valign="top" width="77%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Computer hardware and software/font/div /td td valign="top" width="5%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new ro man"#160;/font/td td valign="top" width="12%" style="TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3-5 years/font/div /td /trtr td valign="top" width="77%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Office equipment/font/div /td td valign="top" width="5%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="top" width="12%" style="TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN - -LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3-5 years/font/div /td /trtr td valign="top" width="77%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Furniture and fixtures/font/div /td td valign="top" width="5%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="top" width="12%" style="TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5-7 yea rs/font/div /td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Leasehold improvements and leased assets are amortized using a straight-line basis over the related lease term or estimated useful life of the assets, whichever is less.#160;#160;The cost and related accumulated depreciation of assets sold or retired are removed from the accounts with the gain or loss, if applicable, recorded in the statement of operations.#160;#160;Maintenance and repair costs are expensed as incurred./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN - -RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Costs relating to the development of software for internal purposes are charged to expense until technological feasibility is established in accordance with Accounting Standards Codification (#8220;ASC#8221;) Topic 350, font style="DISPLAY: inline; FONT-STYLE: italic"Intangibles #8211; Goodwill and Other/font (#8220;ASC 350#8221;). Thereafter, the remaining software production costs up to the date placed into production are capitalized and included as Property and Equipment.#160;#160;Amortization of the capitalized amounts commences on the date the asset is ready for its intended use and is calculated using the straight-line method over the estimated useful life of the software./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0p t; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"#160;#160;#160;#160; Amounts due to Plan Sponsors/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Amounts due to Plan Sponsors primarily represent overpayments that will be paid back to Plan Sponsors in Specialty Pharmacy Services. In addition, these payables include the sharing of manufacturer#8217;s rebates with Plan Sponsors in the Traditional Pharmacy Services segment./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Rebates/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Manufacturers#8217; rebates are primarily part of the Company#8217;s Specialty Pharmacy Services segment.#160;#160;Rebates are generally volume-based incentives that are earned and recorded upon dispense.#160;#160;Volume-based rebates are recorded as a reduction of both inventory and cost of goods sold./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justi fy"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Traditional Pharmacy Services segment also includes rebates earned on the PBM portion of the business.#160;#160;Rebates are recorded on historical PBM results and trends and are revised on a regular basis depending on the Company#8217;s latest forecasts, as well as information received from rebate sources.#160;#160;Should actual results differ, adjustments will be recorded in future earnings when the adjustment becomes known.#160;#160;In some instances, rebate payments are shared with the Company#8217;s Plan Sponsors.#160;#160;PBM rebates earned by the Company are recorded as a reduction of cost of goods sold.#160;#160;PBM rebates shared with clients are recorded as a reduction of revenue consistent with the sales incentive provisions of ASC#160;#160;Topic 605, font style="DISPLAY: inline; FONT-STYLE: italic"Revenue Recognition lt;/font (#8220;ASC 605#8221;)./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Revenue Recognition/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company generates revenue principally through the sale of prescription drugs, which are dispensed either through a pharmacy participating in its pharmacy network or a pharmacy owned by the Company. Revenue is generally derived under fee-for-service agreements. Fee-for-service agreements include: (i) mp;#160;specialty and mail service agreements, where the Company dispenses prescription medications through its pharmacy facilities and (ii)#160;PBM agreements, where prescription medications are dispensed through pharmacies participating in the Company#8217;s retail pharmacy network as well as through its traditional mail service facility./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Accounting Standards Codification (#8220;ASC#8221;) Subtopic 605-25, font style="DISPLAY: inline; FONT-STYLE: italic"Revenue Recognition: Multiple-Element Arrangements/font (#8220;ASC 605-25#8221;), addresses situations in which there are multiple deliverables under one revenue arrangement with a customer and provides gui dance in determining whether multiple deliverables should be recognized separately or in combination.#160;#160;The Company provides a variety of therapies to patients.#160;#160;For infusion related therapies the Company frequently provides the multiple deliverables of drug delivery and related nursing services.#160;#160;After applying the criteria from ASC 605-25, the Company concluded that separate units of accounting exist in revenue arrangements where we provide multiple deliverables./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Under fee-for-service agreements in the Specialty Pharmacy Services segment, drug revenue is recognized at the time the drug is shipped, and nursing revenue is recognized on the date of se rvice. At that point, the earnings process is considered complete and the Company has substantially accomplished the terms of its transaction.#160;#160;In the Traditional Pharmacy Services segment, revenue is recognized#160;when the pharmacy services are reported to the Company through the point of sale (#8220;POS#8221;) claims processing system and the drug is dispensed to the member./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Revenue generated under PBM agreements is classified as either gross or net by the Company based on whether it is acting as a principal or an agent in the fulfillment of prescriptions through its retail pharmacy network. When the Company independently has a contractual obligation to pay a network pharmacy provider for benefits provided to its Plan Sponsors#8217; members, and therefore is the #8220;primary obligor#8221; as defined in ASC Topic 605, font style="DISPLAY: inline; FONT-STYLE: italic"Revenue Recognition,/font the Company includes payments (which include the drug ingredient cost) from these Plan Sponsors as revenue and payments to the network pharmacy providers as cost of revenue. These transactions require the Company to pay network pharmacy providers, assume credit risk of Plan Sponsors and act as a principal. If the Company merely acts as an agent, and consequently administers Plan Sponsors#8217; network pharmacy contracts, it does not have the primary obligation to pay the network pharmacy and assume credit risk and as such records only the administrative fees (and not the drug ingredient cost) as revenue./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY : block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Cost of Revenue/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Cost of revenue includes the costs of prescription medications, pharmacy claims, fees paid to pharmacies, shipping and other direct and indirect costs associated with pharmacy management and administration, claims processing operations, mail order services and nursing services, offset by volume and prompt pay discounts received from pharmaceutical manufacturers and distributors and total manufacturer rebates./font/divbr / div style="DISPLAY: block; MARGI N-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Impairment of Long Lived Assets/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company evaluates whether events and circumstances have occurred that indicate the remaining estimated useful life of long lived assets, including intangible assets, may warrant revision or that the remaining balance of an asset may not be recoverable. The measurement of possible impairment is based on the ability to recover the balance of assets from expected future operating cash flows on an undiscounted basis. Impairment losses, if any, are determined based on the present value of the cash flows using discount rates that reflect the inherent risk of the underlying business./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Goodwill/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In accordance with ASC 350, the Company evaluates goodwill for impairment on an annual basis and whenever events or circumstances exist that indicate that the carrying value of goodwill may no longer be recoverable.#160;#160;The impairment evaluation is ba sed on a two-step process.#160;#160;The first step compares the fair value of a reporting unit with its carrying amount, including goodwill.#160;#160;If the first step indicates that the fair value of the reporting unit is less than its carrying amount, the second step must be performed which determines the implied fair value of reporting unit goodwill. The measurement of possible impairment is based upon the comparison of the implied fair value of reporting unit to its carrying value./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Lease Accounting/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MA RGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company accounts for leasing transactions by recording rent expense on a straight-line basis over the expected life of the lease, starting on the date it gains possession of leased property. Lease terms are generally five years, with many containing options to extend for periods ranging from one to five years. The Company includes tenant improvement allowances and rent holidays received from landlords and the effect of any rent escalation clauses as adjustments to straight-line rent expense over the expected life of the lease.#160;#160;The Company does not enter into capital lease obligations due to certain covenant requirements in our credit facility./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MA RGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Income Taxes/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"As part of the process of preparing the Company#8217;s Consolidated Financial Statements, management is required to estimate income taxes in each of the jurisdictions in which it operates. The Company accounts for income taxes under ASC Topic 740, font style="DISPLAY: inline; FONT-STYLE: italic"Income Taxes/font (#8220;ASC 740#8221;). ASC 740 requires the use of the asset and liability method of accounting for income taxes. Under this method, deferred taxes are determined by calculating the future tax con sequences attributable to differences between the financial accounting and tax bases of existing assets and liabilities. A valuation allowance is recorded against deferred tax assets when, in the opinion of management, it is more likely than not that the Company will not be able to realize the benefit from its deferred tax assets./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company files income tax returns, including returns for its subsidiaries, as prescribed by Federal tax laws and the tax laws of the state and local jurisdictions in which it operates.#160;#160;The Company#8217;s uncertain tax positions are related to tax years that remain subject to examination and are recognized in the Consolidated Financial Statements whe n the recognition threshold and measurement attributes of ASC 740 are met.#160;#160;Interest and penalties related to unrecognized tax benefits are recorded as income tax expense./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Disclosure of Fair Value of Financial Instruments/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company#8217;s financial instruments consist mainly of cash and cash equivalents and its line of credit. The carrying amount s of cash, cash equivalents and the line of credit approximate fair value due to their fully liquid or short-term nature./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Accounting for Stock-Based Compensation/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company accounts for stock-based employee compensation expense under the provisions of ASC Topic 718, font style="DISPLAY: inline; FONT-STYLE: italic"Compensation #8211; Stock Compensation/f ont (#8220;ASC 718#8221;).#160;#160;At December#160;31, 2009, the Company has one stock-based employee compensation plan (the #8220;Plan#8221;) pursuant to which incentive stock options (#8220;ISOs#8221;), non-qualified stock options (#8220;NQSOs#8221;), restricted stock, performance units and performance share awards may be granted to employees and non-employee directors. Option and stock awards are typically settled by issuing authorized but unissued shares of the Company./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company estimates the fair value of each stock option award on the measurement date using a binomial option-pricing model.#160;#160;The fair value of the award is amortized to expense on a straight line basis over the requisite service period. The Company expenses restricted stock awards based on vesting requirements, including time elapsed, market conditions and/or performance conditions.#160;#160;Because of these requirements, the weighted average period for which the expense is recognized varies./font/divbr / div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"#160;Income (Loss) Per Share/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Basic income (loss) per common share is based on the w eighted average number of shares outstanding. Diluted income per share is based on the weighted average number of shares outstanding, including common stock equivalents, and diluted (loss) per share is based on the weighted average number of shares outstanding because the impact of common stock equivalents would be anti-dilutive (in thousands except per share data):/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div align="left" table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td align="right" valign="bottom" style="PADDIN G-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2009/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2008/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2007/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td ;/trtr bgcolor="#cceeff" td valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Numerator:/font/div /td td valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td gt; td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Net income (loss):/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"54,099/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font t;/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(74,032/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,317/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLA Y: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Denominator - Basic:/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bott om" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Weighted average number of common shares outstanding/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#1 60;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"38,985/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALI GN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"38,417/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"37,647/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font t;/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Basic income (loss) per common share/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1.39/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(1.93/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; T EXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"0.09/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Denominator - Diluted:/font/div /td td valign="bottom" width="1%"font style="DISPLA Y: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: time s new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-IN DENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Weighted average number of common shares outstanding/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"38,985/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; ;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"38,417/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"37,647/font/td td nowrap="nowr ap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Common share equivalents of outstanding stock options and restricted awards/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FO NT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"752/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" wi dth="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"844/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MA RGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Total diluted shares outstanding/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"39,737/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DI SPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"38,417/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td val ign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"38,491/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Diluted income (loss) per common share/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" mp;#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1.36/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(1.93/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"0.09/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /tr/ table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Employee stock options and restricted stock awards of 3,681,109, 3,996,523 and 3,259,893 for 2009, 2008 and 2007, respectively, were excluded from the diluted net income per share calculation because their effect would be anti-dilutive./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Recent Accounting Pronouncements/font/d iv div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In June 2009, FASB issued Accounting Standards Update No. 2009-01, font style="DISPLAY: inline; FONT-STYLE: italic"Generally Accepted Accounting Principles/font (#8220;ASC Topic 105#8221;) which established the FASB Accounting Standards Codification (the #8220;Codification#8221;) as the official single source of authoritative GAAP.#160;#160;All previously existing accounting standards were superseded at that date.#160;#160;All other accounting guidance not included in the Codification will be considered non-authoritative.#160;#160;The Codification also includes relevant SEC guidance organized using the same topical structure in separate sections within the Codification./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Following the Codification, FASB has stated that it will not issue new standards in the form of Statements, FASB Staff Positions or Emerging Issues Task Force Abstracts.#160;#160;Instead, it will issue Accounting Standards Updates (#8220;ASU#8221;) that will serve to update the Codification, provide background information about the guidance and provide the basis for conclusions on the changes to the Codification./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE : 10pt; FONT-FAMILY: Times New Roman"The Codification is not intended to change GAAP, but will change the way GAAP is organized and presented.#160;#160;The Codification was effective for the Company#8217;s third quarter 2009 financial statements and the principal impact is limited to disclosures as all future references to authoritative accounting literature will be referenced in accordance with the Codification./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In September 2009, FASB issued ASU 2009-13, font style="DISPLAY: inline; FONT-STYLE: italic"Multiple Element Arrangements /font(#8220;ASU 2009-13#8221;), which is effective for fiscal years beginning on or after June 15, 2010.#160;#160;Earl y adoption is permitted.#160;#160;If early adoption is elected and the period of adoption is not the beginning of the entity#8217;s fiscal year, the entity will be required to apply the amendments of this ASU retrospectively from the beginning of the entity#8217;s fiscal year.#160;#160;An entity may elect, but will not be required, to adopt the amendments in this ASU retrospectively for all prior periods. However, an entity cannot apply the amendments in this ASU retrospectively to a period if it is impracticable for it to report the change through retrospective application to that prior period. /font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"ASU 2009-13 addresses the determination of when the individual deliverables i ncluded in a multiple arrangement may be treated as separate units of accounting. ASU 2009-13 also eliminates the residual method of allocation and requires that arrangement consideration be allocated at the inception of the arrangement to all deliverables using the relative selling price method. This standard must be adopted by the Company no later than January#160;1, 2011. The Company is currently evaluating the impact, if any, that this standard update will have on its results of operations, financial position or cash flows./font/div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"#160;/div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; amp;#160;#160;#160;#160;#160;#160;#160;In 2009, the Company adopted the provisions of ASC Topic#160;855, font style="DISPLAY: inline; FONT-STYLE: italic"Subsequent Events/font (#8220;ASC 855#8221;), which was effective for interim and annual periods after June 15, 2009 and amended on February 24, 2010.#160;#160;This Statement incorporates guidance into accounting literature that was previously addressed only in auditing standards. The statement refers to subsequent events that provide additional evidence about conditions that existed at the balance-sheet date as #8220;recognized subsequent events#8221;.#160;#160;Subsequent events which provide evidence about conditions that arose after an issuer#8217;s most recent balance-sheet date but prior to the issuance of its most recent financial statements are referred to as #8220;non-recognized subsequent events#8221;.#160;#160;It also requir es companies to evaluate subsequent events through the date the financial statements were issued./fontbr //div /div /div

NOTE 3 - OPERATING SEGMENTS	12 Months Ended
NOTE 3 - OPERATING SEGMENTS	Dec. 31, 2009
Notes to Financial Statements [Abstract]
OPERATING SEGMENTS	div div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"NOTE#160;3#160;#8212; OPERATING SEGMENTS/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In accordance with ASC Topic 280, font style="DISPLAY: inline; FONT-STYLE: italic"Segment Reporting/font (#8220;ASC 280#8221;), and based on the nature of the Company#8217;s services, the Company has two operating and reportable segments: Specialty Pharmacy Services and Traditional Pharmacy Services.#160; amp;#160;ASC 280 requires an enterprise to report segment information in the same way that management internally organizes its business for assessing performance and making decisions regarding allocation of resources.#160;#160;The Company evaluates the performance of operating segments and allocates resources based on income from operations./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Revenues from Specialty Pharmacy Services and Traditional Pharmacy Services are derived from the Company#8217;s relationships with healthcare payors including Plan Sponsors as well as from our relationship with pharmaceutical manufacturers, patients and physicians./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt" t;br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Specialty Pharmacy Services segment consists of the Company#8217;s specialty pharmacy distribution and therapy management services.#160;#160;Specialty Pharmacy Services distribution occurs locally through community pharmacies, centrally through mail order facilities and through our infusion pharmacies for patients requiring infused medications in the home or infused at a variety of sites including the Company#8217;s ambulatory infusion sites.#160;#160;All Specialty Pharmacy Services target certain specialty medications that are used to treat patients living with chronic and other complex healthcare conditions./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPL AY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Traditional Pharmacy Services segment consists mainly of traditional mail order pharmacy fulfillment, and to a lesser extent, prescription discount card programs and integrated PBM services.#160;#160;These Traditional Pharmacy Services are designed to offer Plan Sponsors cost-effective delivery of pharmacy benefit plans including the low cost distribution of mail services for plan members who receive traditional maintenance medications./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In the quarter ended September 30, 2009, the Company renamed the reportable segment formerly known as #8220;PBM Services#8221; to #8220;Traditional Pharmacy Services#8221;.#160;#160;The decision to rename this segment reflects a shift in the nature of the business included within this segment away from fully funded pharmacy benefit management services and more towards traditional mail services and prescription discount card programs./font/div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"#160;/div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The accounting policies applied to the business segments are the same as those described in Note 2 -#160;#160;Summary of Significant Accounting Policies. Certain prior period amounts have been reclassified to conform to the current year presentation. Such reclass ifications are deemed immaterial to segment data presented below.#160;#160;There is no effect on previously reported net income (loss) from operations./font/div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"#160;/divbr / div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Segment Reporting Information/font/div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"(in thousands)/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"br / /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div align="left" table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="8" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Years E nded December 31,/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT - -WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2009/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2008/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan= "2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2007/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Revenue:/font/div /td td valign="bottom"font style="DISPL AY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Specialty Pharmacy Services/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,113,305/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,196,587/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left" lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"974,571/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Traditional Pharmacy Services/font/div /td td align="right" valign="bottom" wid th="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"216,220/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roma n"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"205,324/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"223,161/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDIN G-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;#160;#160;Total/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roma n"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,329,525/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,401,911/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4 px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,197,732/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0p t" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Income (loss) from operations:/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font s tyle="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Specialty Pharmacy Services/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(1,320/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(93,120/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font /td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(2,453/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Traditional Pharmacy Services/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: time s new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"16,786/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTT OM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"9,603/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"11,304/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new r oman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;#160;#160;Total/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" t;15,466/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(83,517/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"8,851/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Interest expense, net/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="T EXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,920/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,711/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,270/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Income tax (benefit) provision/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(40,553/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width ="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(12,196/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAM ILY: times new roman"2,264/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Net income (loss):/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"54,099/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(74,032/font/td td nowr ap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,317/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" div style="DISPLAY: block; MARG IN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Capital expenditures:/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign= "bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Specialty Pharmacy Services/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right" t;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5,074/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6,280/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZ E: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"4,843/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Traditional Pharmacy Services/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"f ont style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"665/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,183/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"683/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DI SPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;#160;#160;Total/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5,739/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"7,463/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FO NT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5,526/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Depreciation Expense:/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: tim es new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" mp;#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Specialty Pharmacy Services/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"4,206/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,919/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9% " style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,691/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Traditional Pharmacy Services/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"827/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font sty le="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"538/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"501/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;#160;#160;Total/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: i nline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5,033/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"4,457/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bott om" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"4,192/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Total Assets/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right" font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" wid th="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Specialty Pharmacy Services/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"208,521/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; F ONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"180,237/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"232,823 /font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Traditional Pharmacy Services/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font sty le="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"78,699/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"66,720/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"63,999/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" style="PADDING-BOTTOM: 4p x" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;#160;#160;Total/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"287,220/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"246,957/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inlin e; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"296,822/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /tr/table /div /div /div

NOTE 9 - INCOME TAXES	12 Months Ended
NOTE 9 - INCOME TAXES	Dec. 31, 2009
Notes to Financial Statements [Abstract]
INCOME TAXES	div div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"NOTE#160;9#160;#8212; INCOME TAXES/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company#8217;s Federal and state income tax provision (benefit) is summarized in the following table (in thousands):/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div align="left" table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr td valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="10" valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"For the Years Ended December 31,/font/div /td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt ; FONT-FAMILY: times new roman"#160;/font/td /trtr td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2009/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style= "DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2008/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="botto m" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2007/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify" font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Current/font/div /td td valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="n owrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160; #160;#160;Federal/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(319/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(18/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"fon t style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(501/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;State/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: bl ack 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"283/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/f ont/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"43/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(43/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td /trtr bgcolor="white" td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Total Current/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1% " style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(36/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" ;#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"25/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: r ight"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(544/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Deferred/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: tim es new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Federal/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(36,764/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(10,660/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" #160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,448/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;State/font /div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(3,753/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font styl e="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(1,561/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"360/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Total Deferred/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(40,517/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOT TOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(12,221/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,808/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Total (Benefit from) Provision for Income Taxes/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(40,553/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td align="right" valign="bottom" width="1%" s tyle="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(12,196/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,264/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //divbr / div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" gt;The effect of temporary differences that give rise to a significant portion of deferred taxes is as follows (in thousands):/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div align="left" table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="5" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"December 31,/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style=" BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2009/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2008/font/div /td td nowrap="nowrap" valign="botto m" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Deferred tax assets:/font/div /td td valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT- FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="76%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Reserves not currently deductible/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"7,131/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6,533/font/td td nowrap="nowrap" v align="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="76%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Net operating loss carryforwards/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" wid th="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,595/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"8,455/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" t d valign="bottom" width="76%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Intangibles/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"4,817/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY : inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5,310/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="76%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160; #160;#160;Goodwill (tax deductible)/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"14,794/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new rom an"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"17,720/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="76%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Accrued expenses/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/f ont/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,117/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,091/font/td td nowra p="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="76%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Stock based compensation/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,342/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,653/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" lt;td valign="bottom" width="76%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Property basis differences/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,025/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left" ;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,666/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMIL Y: times new roman"#160;#160;#160;#160;Other/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,885/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,411/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="76%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160; #160;#160;#160;Subtotal deferred tax assets/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"39,706/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAM ILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"44,839/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="76%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Deferred tax liabilities:/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" vali gn="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="76%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Goodwill (tax deductible)/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(533/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="76%" style="P ADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Less: valuation allowance/font/div /td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(44,839/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td /trtr bgcolor="white" td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px" div s tyle="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;#160;#160;Net deferred tax asset (liability)/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"39,706/font/td td now rap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(533/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div t;div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company continually assesses the ability to realize the benefit of its deferred tax assets.#160;#160;In the fourth quarter of 2006 a valuation allowance on deferred tax assets was recorded.#160;#160;During the fourth quarter of 2009, based upon an evaluation of the positive and negative evidence, the Company concluded that the valuation allowance in the amount of $44.8 million was no longer required.#160;#160;As part of its analysis, the Company evaluated, among other factors, its recent history of generating taxable income, the underlying factors which resulted in the goodwill impairment charge that was incurred during the fourth quarter of 2008, and its near-term forecasts of future taxable incom e.#160;#160;After considering these factors, the Company concluded that a reversal of the valuation allowance was appropriate.#160;#160;Accordingly, the Company recognized a tax benefit of $44.8 million during the 2009 fourth quarter./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"At December#160;31, 2009, the Company had Federal net operating loss (#8220;NOL#8221;) carryforwards of approximately $18.0#160;million, of which $3.2#160;million is subject to an annual limitation, all of which will begin expiring in 2012 and later.#160;#160;Of the Company#8217;s $18.0 million Federal NOLs, $8.5 million will be recorded in additional paid-in capital when realized.#160;#160;These NOL s are related to the exercise of non-qualified stock options.#160;#160;The Company has post apportioned state NOL carryforwards remaining of approximately $8.1#160;million, the majority of which will begin expiring in 2017 and later./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company#8217;s reconciliation of the statutory rate to the effective income tax rate is as follows (in thousands):/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div align="left" table cell padding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2009/font/div /td td nowrap="nowrap" valign="bottom" style="PADD ING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2008/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2007/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Tax (benefit) provision at statutory rate/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td ;td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"4,566/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(29,310/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-AL IGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,897/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"State ta x (benefit) provision, net of Federal taxes/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"633/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new rom an"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(2,616/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"366/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td t; /trtr bgcolor="#cceeff" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Non-deductible goodwill/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: lef t"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,687/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; F ONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Change in tax contingencies/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160 ;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(216/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(360/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td va lign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(1,165/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Valuation allowance changes affecting income tax expense/font/div /td td align="right" valign= "bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(44,839/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"18,245/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"930/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" div styl e="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Change in deferred tax rate/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(992/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Other/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom " width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"295/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"158/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt ; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"236/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Provision for income taxes/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(40,553/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman ")/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(12,196/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" ;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,264/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"As of December 31, 2009 the Company had $1.9 million of total gross unrecognized tax benefits, all of which, if recognized, would favorably affect its effective income tax rate in future periods.#160;#160;A reconciliation of the beginning a nd ending amount of gross unrecognized tax benefits is as follows (in thousands):/font/divbr / div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"#160;/div div align="left" table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DI SPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2009/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2008/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT - -WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2007/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Unrecognized tax benefits balance at January 1,/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,287/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMI LY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,940/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"4,137/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font /td /trtr bgcolor="white" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Gross increases for tax positions of prior years/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" w idth="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"fo nt style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"284/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Gross decreases for tax positions of prior years/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FON T-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(239/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman") ;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(380/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td /trtr bgcolor="white" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Gross increases for tax positions taken in current year/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right "font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Settlements with taxing authorities/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; lt;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(46/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(114/font/td td nowrap="nowr ap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td /trtr bgcolor="white" td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Lapse of statute of limitations/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(339/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(368/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DIS PLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(993/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font s tyle="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Unrecognized tax benefits balance at December 31,/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,948/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" #160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,287/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN : right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,940/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company's policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of income tax expense in the statement of operations.#160;#160;As of December 31, 2009 and December 31, 2008, the Company had approximately $0.5 million and $0.5 million#160;#160;of accrued interest related to uncertain tax positions, respectively./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company files income tax returns, including returns for its subsidiaries, with Federal, state and local jurisdictions.#160;#160;The Company's uncertain tax positions are related to tax years that remain subject to examination.#160;#160;As of December 31, 2009, U.S. tax returns for 2006, 2007, 2008 and 2009 remain subject to examination by Federal tax authorities.#160;#160;Tax returns for the years 2005 through 2009 remain subject to examination by state and local tax authorities for a majority of the Company's state and local filings./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"During January 2008, the Company settled certain controversies with taxing authorities.#160;#160;The settlement called for payment of $63,000 of tax and interest.#160;#160;The remaining amount of $0.3 million of unrecognized tax benefits and interest for this tax position was reversed during first quarter 2008 through goodwill./font/div /div /div

NOTE 11 - STOCK-BASED COMPENSATION	12 Months Ended
NOTE 11 - STOCK-BASED COMPENSATION	Dec. 31, 2009
Notes to Financial Statements [Abstract]
STOCK-BASED COMPENSATION PLANS	div div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"NOTE#160;11#160;#8212; STOCK-BASED COMPENSATION/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Under the Company#8217;s 2008 Equity Incentive Plan (the #8220;2008 Plan#8221;) the Company may issue, among other things, incentive stock options (#8220;ISOs#8221;), non-qualified stock options (#8220;NQSOs#8221;), stock appreciation rights, restricted stock, and performan ce units to employees and directors.#160;#160;Under the 2008 Plan, 3,580,000 shares were authorized for issuance (subject to adjustment for grants made under the Company#8217;s 2001 Incentive Stock Plan (the #8220;2001 Plan#8221;) after January 1, 2008, as well as for forfeitures, expirations or awards that under the 2001 Plan otherwise settled in cash after the adoption thereof).#160;#160;As of December 31, 2009 209,253 shares remained available for grant under the 2008 Plan.#160;#160;Upon effectiveness of the 2008 Plan in April 2008, the Company ceased making grants under the 2001 Plan.#160;#160;The 2008 Plan and the 2001 Plan are administered by the Company#8217;s Management Development and Compensation Committee (the #8220;Compensation Committee#8221;), a standing committee of the Board./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLA Y: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Under the terms of the 2008 Plan and the 2001 Plan, plan participants may use shares to cover tax withholding on income earned as a result of appreciation of equity-based instruments upon exercise, vesting and/or lapsing of restrictions thereon.#160;#160;Upon the exercise of stock options and the vesting of other equity awards granted under the Plans, participants will generally have taxable income subject to statutory withholding requirements.#160;#160;The number of shares that may be issued to participants upon the exercise of stock options and the vesting of equity awards may be reduced by the number of shares having a market value equal to the amount of tax required to be withheld by the Company to satisfy Federal, state and local tax obligations as a result of such exercise or vesting./font/div t; div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Stock Options/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Options granted under the plans: (a) typically vest over a three-year period and, in certain instances, fully vest upon a change in control of the Company, (b) have an exercise price that may not be less than 100% of its fair market value on the date of grant (110% for ISOs granted to a stockholder who holds more than 10% of the outstanding stock of the Company), and (c) are generally exercisable for ten years (five years for ISOs granted to a stockholder /fontfont style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"holding more than 10% of the outstanding stock of the Company) after the date of grant, subject to earlier termination in certain circumstances./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company recognized compensation expense related to stock options of $2.2 million, $2.1 million and $1.9 million for the years ended December 31, 2009, 2008 and 2007, respectively./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT : 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The fair value of each stock option award on the date of the grant was calculated using a binomial option-pricing model.#160;#160;Option expense is amortized on a straight-line basis over the requisite service period and was calculated with the following weighted average assumptions:/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div align="left" table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2009/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT : 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2008/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2007/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY : times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Expected volatility/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"66.4/font/td t d nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"%/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"51.4/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"%/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALI GN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"54.4/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"%/font/td /trtr bgcolor="white" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Risk-free interest rate/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT - -FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2.99/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"%/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3.86/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"%/font gt;/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"4.70/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"%/font/td /trtr bgcolor="#cceeff" td valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Expected life of options/font/div /td td valign="bottom"font s tyle="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="TEXT-ALIGN: right" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5.6 years/font/div /td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="TEXT-ALIGN: right" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5.7 years/font/div /td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="TEXT-ALIGN: right" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5.2 years/font/div /td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Dividend rate/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/t d td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr b gcolor="#cceeff" td valign="bottom" width="64%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Fair value of options/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1.70/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLA Y: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3.46/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" t;2.29/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Stock option activity through December#160;31, 2009 is as follows:/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div align="left" table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr td valign="bottom" width=" 40%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Weighted/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Aggregate/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Weighted Average/font/div /td /trtr td valign="bottom" width="40%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" div style="DISPLAY: block; MARGI N-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Average/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Intrinsic Value/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/f ont/td td valign="bottom" width="9%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Remaining/font/div /td /trtr td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center "font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Options/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Exercise Price/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" ;#160;/font/td td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(thousands)/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Contractual Life/font/ div /td /trtr bgcolor="#cceeff" td valign="bottom" width="40%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Balance, December 31, 2008/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5,784,371/font/td td nowrap="n owrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6.53/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right" gt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"27.5/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5.6 years/font/div /td /trtr bgcolor="white" td valign="bottom" width="40%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Granted/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,918,600/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td va lign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2.84/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" gt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td /trtr bgcolor="#cceeff" td valign="bottom" width="40%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Exercised/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FON T-SIZE: 10pt; FONT-FAMILY: times new roman"(889,606/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3.39/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td /trtr bgcolor="white" td valign="bottom" width="40%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Forfeited/font/div /t d td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(182,974/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" styl e="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"4.86/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%"font style="DISPLAY: i nline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td /trtr bgcolor="#cceeff" td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Expired/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="B ORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(580,334/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"7.01/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; lt;/font/td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td /trtr bgcolor="white" td valign="bottom" width="40%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Balance, December 31, 2009/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6,050,057/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOT TOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5.83/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="PADDING- BOTTOM: 4px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"19,014.1/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6.2 years/font/div /td /trtr bgcolor="#cceeff" td valign="bottom" width="40%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times n ew roman"Outstanding options less expected/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" gt;#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/f ont/td td valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td /trtr bgcolor="white" td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;forfeitures at December 31, 2009/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT - -FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5,430,876/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6.09/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"16,023.4/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: in line; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5.9 years/font/div /td /trtr bgcolor="#cceeff" td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Exercisable at December 31, 2009/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9% " style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,589,751/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"7.32/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font t;/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"7,437.5/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"4.6 years/font/div /td /tr/table t; /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The weighted-average, grant-date fair value of options granted during the years ending December#160;31, 2009, 2008 and 2007 was $1.70, $3.46 and $2.29 respectively. The total intrinsic value of options exercised during the years December#160;31, 2009, 2008, and 2007, was $3.0#160;million, $0.1#160;million, and $1.3 million, respectively./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Cash received from option exercises under share-based payment arrangements for the years ended December#160;31, 2009, 2008, and 2007, was $3.0#160;million, $0.2 million and $1.9#160;million, respectively./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The maximum term of stock options under these plans is ten years. Options outstanding as of December#160;31, 2009 expire on various dates ranging from August 2010 through October 2019. The following table outlines our outstanding and exercisable stock options as of December#160;31, 2009:/font/div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font st yle="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;/fontbr /#160;/div div align="left" table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr td valign="bottom" width="31%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="7" valign="bottom" width="32%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: i nline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Options Outstanding/font/div /td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="5" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Options Exercisable/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr td valign="bottom" width="31%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGH T: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Weighted/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY : times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Weighted/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr td valign="bottom" width="31%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; lt;/font/td td colspan="2" valign="bottom" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Average/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bot tom" width="9%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Weighted Average/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MAR GIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Average/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr td valign="bottom" width="31%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center" font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Outstanding/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Exercise/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Remaining/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Options/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; ;/font/td td colspan="2" valign="bottom" width="10%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Exercise/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr td valign="bottom" width="31%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Range of Option Exercise Price/font/div / td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Options/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid" div sty le="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Price/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Contractual Life/font/div /td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZ E: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Exercisable/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: t imes new roman"Price/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="30%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160; $1.50 - $4.69/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,584,801/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2.65/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"7.96 years/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"806,141/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" gt;#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2.80/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="30%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160; $5.29 - $7.03/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DIS PLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,811,021/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT- FAMILY: times new roman"6.35/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5.68 years/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-A LIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,196,707/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6.35/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom " width="30%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160; $7.16 - $9.56/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,062,648/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"7.87/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5.20 years/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FA MILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"995,316/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"7.90/fon t/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="30%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160; $9.77 - $12.20/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"344,920/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"12.01/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT : 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1.93 years/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"344,920/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style= "TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"12.01/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="30%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160; $16.50 - $20.25/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT- FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"246,667/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="PADDING-B OTTOM: 2px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"17.92/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2.04 years/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; T EXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"246,667/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"17.92/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="30%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: b lack 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6,050,057/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5.83/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6.21 years/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,589,751/font/td td n owrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"7.32/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGI N-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"As of December#160;31, 2008 and 2007, the exercisable portion of outstanding options was approximately 4.2#160;million shares and approximately 3.7#160;million shares, respectively./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Stock option activity for non-vested shares through December#160;31, 2009 is as follows:/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div align="left" table cellpadding="0" cel lspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr td valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPL AY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Weighted/font/div /td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr td valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY : times new roman"#160;/font/td td colspan="2" valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Average/font/div /td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr td valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom"font s tyle="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Grant Date/font/div /td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAM ILY: times new roman"#160; /font/td td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Options/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGI N-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Fair Value/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="76%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Balance, December 31, 2008/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/ font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,614,718/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2.70/font/td td nowrap="no wrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="76%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Granted/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-A LIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,918,600/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1.71/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom " width="76%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Vested/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(640,973/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZ E: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2.56/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="76%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Exercised/f ont/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(203,204/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1.85/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Forfeited and expired/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160 ;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(228,835/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"font st yle="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2.31/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Balance, December 31, 2009/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTT OM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,460,306/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2.07/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"As of December 31, 2009 there was $3.1 million of unrecognized compensation expense related to unvested option grants.#160;#160;That expense is expected to be recognized over a weighted-average period of 2.0 years./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"As compensation expense for options granted is recorded over the requisite service period of options, future stock-based compensation expense may be greater as additional options are granted./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Restricted Stock/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Under the 2008 Plan, stock grants subject solely to an employee#8217;s or dir ector#8217;s continued service with the Company will not become fully vested less than (a) three years from the date of grant to employees and, in certain instances, may fully vest upon a change in control of the Company, and (b) one year from the date of grant for directors.#160;#160;Stock grants subject to the achievement of performance conditions will not vest less than one year from the date of grant where the vesting of stock grants is subject to performance measures.#160;#160;Such performance shares may vest after one year from grant.#160;#160;No such time restrictions applied to stock grants made under the Company#8217;s prior equity compensation plans./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" t;The Company recognized compensation expense related to restricted stock awards of $1.2 million, $1.7 million and $1.1 million for the years ended December 31, 2009, 2008 and 2007, respectively./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Since the Company records compensation expense for restricted stock awards based on the vesting requirements, which generally includes time elapsed, market conditions and/or performance conditions, the weighted average period over which the expense is recognized varies. Also, future equity-based compensation expense may be greater if additional restricted stock awards are made./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style ="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Restricted stock award activity through December#160;31, 2009 is as follows:/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div align="left" table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr td valign="bottom" width="50%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%"font style="DISPLAY: inline; FO NT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Weighted Average/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="26%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RI GHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Weighted Average/font/div /td /trtr td valign="bottom" width="50%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Restricted/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN : left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Award/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="26%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Remaining/font/ div /td /trtr td valign="bottom" width="50%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Stock/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGH T: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Date Fair Value/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="26%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT - -FAMILY: times new roman"Recognition Period/font/div /td /trtr bgcolor="#cceeff" td valign="bottom" width="50%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Balance December 31, 2008/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" ;713,637/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"4.24/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="26%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY : inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1.5 years/font/div /td /trtr bgcolor="white" td valign="bottom" width="50%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Granted/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZ E: 10pt; FONT-FAMILY: times new roman"257,860/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1.76/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="26%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /fon t/td /trtr bgcolor="#cceeff" td valign="bottom" width="50%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Awards Vested/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(132,455/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"4.32/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="26%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td /trtr bgcolor="white" td valign="bottom" width="50%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Canceled/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(93,282/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5.28/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="26%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" #160; /font/td /trtr bgcolor="#cceeff" td valign="bottom" width="50%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Balance December 31, 2009/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inl ine; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"745,760/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3.24/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="26%" style="PADDING-BOTTOM: 4px" ; div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1.1 years/font/div /td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"As of December#160;31, 2009, there was $0.6#160;million of unrecognized compensation expense related to unvested restricted stock awards.#160;#160;That expense is expected to be recognized over a weighted average period of 1.1#160;years. The total grant date fair market value of awards vested during the years ended December#160;31, 2009, 2008 and 2007 was $0.6#160;million, $1.1#160;million and $0.6#160;million, respectively.#160;#160;The total intrinsic value of restricted stock awards vested during the years December 31, 2009, 2008 and 2007 was $0.5 million, $2.3 million and $3.9 million, respectively./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Performance Units/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Under the 2008 Plan, the Compensation Committee may grant performance units to key employee s. The Compensation Committee will establish the terms and conditions of any performance units granted, including the performance goals, the performance period and the value for each performance unit. If the performance goals are satisfied, the Company would pay the key employee an amount in cash equal to the value of each performance unit at the time of payment. In no event may a key employee receive an amount in excess of $1.0 million with respect to performance units for any given year. To date, no performance units have been granted under the 2008 Plan./font/div /div /div

NOTE 13 - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

12 Months Ended

Dec. 31, 2009

Notes to Financial Statements [Abstract]

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

NOTE 13 — SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

A summary of quarterly financial information for fiscal 2009 and 2008 is as follows (in thousands except per share data):

< /tr> < td valign="bottom" width="9%" style="TEXT-ALIGN: right">4,377

	First Quarter		Second Quarter			Third Quarter			Fourth Quarter
2009:
Revenue	$	325,749	$	328,749		$	333,476		$	341,551
Gross profit	$	35,990	$	38,388		$	41,496		$	41,948
N et income (1)	$	3,285	$		$	5,747		$	40,690
Basic income per share	$	0.08	$	0.11

NOTE 14 - SUBSEQUENT EVENTS	12 Months Ended
NOTE 14 - SUBSEQUENT EVENTS	Dec. 31, 2009
Notes to Financial Statements [Abstract]
SUBSEQUENT EVENTS	div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"NOTE#160;14#160;#8212; SUBSEQUENT EVENTS/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Pending Acquisition/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"On January 24, 2010, the Com pany entered into an Agreement and Plan of Merger to acquire Critical Homecare Solutions Holdings, Inc. (#8220;CHS#8221;).#160;#160;CHS is a privately held company that is a leading provider of home infusion and home nursing services and products to patients suffering from chronic and acute medical conditions.#160;#160;Completion of the acquisition is subject to stockholders approval of the issuance of additional shares of the Company#8217;s common stock to CHS stockholders and satisfaction of certain other customary conditions.#160;#160;The acquisition is expected to close on or about March 31, 2010./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"If the merger is completed, the Company will:/font ;/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent_0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr valign="top" td style="WIDTH: 36pt" divfont style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/div /td td style="WIDTH: 18pt" div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif"#183;/font/font/div /td td div align="justify"font style="DISPLAY: inline; FONT-SIZE : 10pt; FONT-FAMILY: Times New Roman"Repay the net indebtedness of CHS, which is approximately $132.0 million at December 31, 2009, and enter into a new credit facility;/font/div /td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent_1" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr valign="top" td style="WIDTH: 36pt" divfont style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/div /td td style="WIDTH: 18pt" div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMI LY: Times New Roman"font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif"#183;/font/font/div /td td div align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Pay cash consideration of $110.0 million, subject to adjustment;/font/div /td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent_2" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr valign="top" td style="WIDTH: 36pt" divfont style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/div ;/td td style="WIDTH: 18pt" div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif"#183;/font/font/div /td td div align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Issue up to approximately 12.9 million shares of BioScrip common stock, subject to adjustment, of which 2,696,516 shares initially will be held in escrow to fund indemnification payments, if any; and/font/div /td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent_3" width="100% " style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr valign="top" td style="WIDTH: 36pt" divfont style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/div /td td style="WIDTH: 18pt" div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline; FONT-FAMILY: Symbol, serif"#183;/font/font/div /td td div align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Issue warrants to acquire approximately 3.4 million shares of BioScrip common stock, exercisable at $10.00 per share and having a five-year term./font/div /td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In order to fund the payment of the cash consideration required to be paid for the acquisition of CHS, refinance#160;the Company's#160;existing indebtedness and repay the existing indebtedness of CHS, the Company has entered into a commitment letter with Jefferies, pursuant to which Jefferies has committed to provide BioScrip with $375.0 million in debt financing, comprised of $150.0 million senior credit facilities and $225.0 million in other indebtedness./font/div /div

Schedule II- Valuation Allowance and Qualifying Accounts	12 Months Ended
	Dec. 31, 2009
Schedule to Financial Statements [Abstract]
Schedule II - Valuation and Qualifying Accounts	div div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Bioscrip, Inc. and Subsidiaries/font/div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Schedule II- Valuation and Qualifying Accounts/font/div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"(in thousands)/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;/fontbr /#160;/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div align="left" table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr td valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Balance at/font/div /td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Write-Off/font/div /td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" gt; div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Charged to/font/div /td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr td valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Beginning of/font/div /td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"of/font/div /td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Costs/font/div /td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="cente r"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Balance at/font/div /td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center "font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Period/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Receivables/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"and Expenses/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"End of Period/font/div /td td nowrap= "nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Year ended December 31, 2007/font/div /td td valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td n owrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="52%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Accounts receivable/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" $/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"13,774/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(6,810/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT - -ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5,119/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"12,083/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Year ended December 31, 2008/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td t;td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom " width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: righ t"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="52%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Accounts receivable/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bo ttom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"12,083/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FON T-FAMILY: times new roman"(5,121/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"4,667/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM : black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"11,629/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Year ended December 31, 2009/font/div /td td valign= "bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font sty le="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="52%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Accounts receivable/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"11,629/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(8,761/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"8,636/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inli ne; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"11,504/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /tr/table /div /div /div

Entity Information - USD ($)	12 Months Ended
Entity Information - USD ($)	Dec. 31, 2009	Feb. 24, 2010	Jun. 30, 2009
Entity Registrant Name	BioScrip, Inc.
Entity Central Index Key	0001014739
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	Yes
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 125,041,731
Entity Common Stock, Shares Outstanding		39,794,757

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007
Income Statement [Abstract]
Revenue	$ 1,329,525	$ 1,401,911	$ 1,197,732
Cost of revenue	1,171,703	1,259,741	1,060,717
Gross profit	157,822	142,170	137,015
Selling, general and administrative expenses	133,720	125,202	120,147
Bad debt expense	8,636	4,667	5,119
Amortization of intangibles	0	1,936	2,898
Goodwill and intangible impairment	0	93,882	0
Income (loss) from operations	15,466	(83,517)	8,851
Interest expense, net	1,920	2,711	3,270
Income (loss) before income taxes	13,546	(86,228)	5,581
Tax (benefit) provision	(40,553)	(12,196)	2,264
Net income (loss)	$ 54,099	$ (74,032)	$ 3,317
Income (loss) per common share
Basic	$ 1.39	$ (1.93)	$ 0.09
Diluted	$ 1.36	$ (1.93)	$ 0.09
Weighted average common shares outstanding
Basic	38,985	38,417	37,647
Diluted	39,737	38,417	38,491

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007
Statement [Line Items]
Balance	$ 95,537	$ 166,203	$ 161,833
Proceeds from exercise of stock options	3,015	465	1,867
Income tax shortfall from stock option plan	(158)
Surrender of stock to satisfy minimum tax withholding	(119)	(889)	(1,397)
Issuance of treasury stock for restricted stock vesting	0
Compensation under employee stock compensation plans	3,419	3,790	3,004
Cumulative effect of accounting pronouncement adoption			(2,421)
Net income (loss)	54,099	(74,032)	3,317
Balance	155,793	95,537	166,203
Common Stock
Statement [Line Items]
Balance	4	4	4
Proceeds from exercise of stock options	0	0	0
Income tax shortfall from stock option plan	0
Surrender of stock to satisfy minimum tax withholding	0	0	0
Issuance of treasury stock for restricted stock vesting	0
Compensation under employee stock compensation plans	0	0	0
Cumulative effect of accounting pronouncement adoption			0
Net income (loss)	0	0	0
Balance	4	4	4
Treasury Stock
Statement [Line Items]
Balance	(10,288)	(9,399)	(8,002)
Proceeds from exercise of stock options	0	0	0
Income tax shortfall from stock option plan	0
Surrender of stock to satisfy minimum tax withholding	(119)	(889)	(1,397)
Issuance of treasury stock for restricted stock vesting	40
Compensation under employee stock compensation plans	0	0	0
Cumulative effect of accounting pronouncement adoption			0
Net income (loss)	0	0	0
Balance	(10,367)	(10,288)	(9,399)
Additional Paid-in Capital
Statement [Line Items]
Balance	248,441	244,186	239,315
Proceeds from exercise of stock options	3,015	465	1,867
Income tax shortfall from stock option plan	(158)
Surrender of stock to satisfy minimum tax withholding	0	0	0
Issuance of treasury stock for restricted stock vesting	(40)
Compensation under employee stock compensation plans	3,419	3,790	3,004
Cumulative effect of accounting pronouncement adoption			0
Net income (loss)	0	0	0
Balance	254,677	248,441	244,186
Accumulated Deficit
Statement [Line Items]
Balance	(142,620)	(68,588)	(69,484)
Proceeds from exercise of stock options	0	0	0
Income tax shortfall from stock option plan	0
Surrender of stock to satisfy minimum tax withholding	0	0	0
Issuance of treasury stock for restricted stock vesting	0
Compensation under employee stock compensation plans	0	0	0
Cumulative effect of accounting pronouncement adoption			(2,421)
Net income (loss)	54,099	(74,032)	3,317
Balance	$ (88,521)	$ (142,620)	$ (68,588)

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007
Cash flows from operating activities:
Net income (loss)	$ 54,099	$ (74,032)	$ 3,317
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation	5,033	4,457	4,192
Amortization	0	1,936	2,898
Goodwill and intangible impairment	0	93,882	0
Change in net deferred income taxes	(40,517)	(12,221)	2,808
Excess tax benefits relating to employee stock compensation	(120)	0	0
Compensation under stock-based compensation plans	3,419	3,790	3,004
Bad debt expense	8,636	4,667	5,119
Changes in assets and liabilities
Receivables, net of bad debt expense	(1,100)	(34,347)	1,050
Inventory	(6,029)	(11,629)	(127)
Prepaid expenses and other assets	(1,237)	(1,923)	859
Accounts payable	(2,401)	19,594	5,618
Claims payable	(1,162)	66	(4,384)
Amounts due to plan sponsors	(708)	1,078	(5,712)
Accrued expenses and other liabilities	4,832	(4,064)	5,545
Net cash provided by (used in) operating activities	22,745	(8,746)	24,187
Cash flows from investing activities:
Purchases of property and equipment, net of disposals	(5,739)	(7,463)	(5,526)
Net cash used in investing activities	(5,739)	(7,463)	(5,526)
Cash flows from financing activities:
Borrowings on line of credit	1,331,000	1,409,003	1,200,760
Repayments on line of credit	(1,351,022)	(1,392,370)	(1,219,891)
Excess tax benefits relating to employee stock compensation	120	0	0
Surrender of stock to satisfy minimum tax withholding	(119)	(889)	(1,397)
Proceeds from exercise of employee stock compensation plans	3,015	465	1,867
Net cash (used in) provided by financing activities	(17,006)	16,209	(18,661)
Net change in cash and cash equivalents	0	0	0
Cash and cash equivalents - beginning of period	0	0	0
Cash and cash equivalents - end of period	0	0	0
DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest	1,918	4,011	3,471
Cash paid during the period for income taxes	$ 741	$ 382	$ 1,599

NOTE 1 - NATURE OF BUSINESS	12 Months Ended
NOTE 1 - NATURE OF BUSINESS	Dec. 31, 2009
Notes to Financial Statements [Abstract]
NATURE OF BUSINESS	div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"NOTE#160;1#160;#8212;#160;NATURE OF BUSINESS/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Corporate Organization and Business/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"B ioScrip, Inc. and subsidiaries (the #8220;Company#8221; or #8220;BioScrip#8221;) is a specialty pharmaceutical healthcare organization that partners with patients, physicians, healthcare payors and pharmaceutical manufacturers to provide access to medications and management solutions to optimize outcomes for chronic and other complex healthcare conditions./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"BioScrip#8217;s business is reported under two operating segments: (i) Specialty Pharmacy Services, and (ii) Traditional Pharmacy Services.#160;#160;The Specialty Pharmacy Services segment includes comprehensive support, dispensing and distribution, patient care management, data reporting, as well as a range of oth er complex therapy management services for certain chronic and acute health conditions.#160;#160;The medications we dispense include oral, injectable and infusible medications which are used to treat patients living with chronic and other complex health conditions.#160;#160;The Traditional Pharmacy Services segment consists mainly of traditional mail service pharmacy fulfillment, and to a lesser extent, prescription discount card programs and fully funded pharmacy benefit management (#8220;PBM#8221;) services./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company distributes high-cost pharmaceuticals and provides clinically focused case and disease management programs to healthcare payors including managed care or ganizations, government-funded and/or operated programs, third party administrators (#8220;TPAs#8221;) and self-funded employer groups (collectively, #8220;Plan Sponsors#8221;), enrollees afflicted with chronic and other complex health conditions. The disease states or conditions for which the Company has such programs include Psoriasis, Growth Hormone Deficiency, Thyroid Cancer, Sickle Cell/Thalassemia, Hemophilia, Multiple Sclerosis, Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Solid Organ Transplants, HIV/AIDS, Hepatitis Camp;B and RSV. The specialty drugs distributed through the BioScrip programs are dispensed and serviced from the Company#8217;s 43 specialty pharmacy locations across the United States./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEI GHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Basis of Presentation/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company#8217;s Consolidated Financial Statements have been prepared in accordance with U.S.#160;generally accepted accounting principles (#8220;GAAP#8221;)./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Reclassification/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Certain prior period amounts have been reclassified to conform to the current year presentation. Such reclassifications had no material effect on the Company#8217;s previously reported consolidated financial position, results of operations or cash flows./font/div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"#160;/div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify" div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Subsequent Events/ font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company has evaluated events that occurred during the period subsequent to the balance sheet date.#160;#160;With the exception of the pending acquisition (See Note 14 #8211; Subsequent Events), there were no subsequent events that require recognition or disclosure in the financial statements./font/div /div /div

NOTE 4 - CONCENTRATION OF CREDIT RISK	12 Months Ended
NOTE 4 - CONCENTRATION OF CREDIT RISK	Dec. 31, 2009
Notes to Financial Statements [Abstract]
CONCENTRATION OF CREDIT RISK	div div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"NOTE#160;4#160;#8212; CONCENTRATION OF CREDIT RISK/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company provides trade credit to its customers in the normal course of business.#160;#160;The following table outlines one pharmacy network agreement under which various Plan Sponsors are served and which Plan Sponsors account for, in the aggregate, revenues and receivables that exceeded 10% of the Company#8217 ;s total revenues and accounts receivables during the applicable time period:/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div align="left" table cellpadding="0" cellspacing="0" width="97%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr td valign="bottom" width="92%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td colspan="3" valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Plan Sponsors Aggregated/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="92%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Year ended December 31, 2007/font/div /td td colspan="2" valign="bottom" width="5%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="3%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="92%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDE NT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;% of total revenue/font/div /td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="4%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"12/font/td td nowrap="nowrap" valign="bottom" width="3%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"%/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="92%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDEN T: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;% of total accounts receivable at period end/font/div /td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="4%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"19/font/td td nowrap="nowrap" valign="bottom" width="3%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"%/font/td /trtr bgcolor="white" td valign="bottom" width="92%" div style="DISPLAY: block; MARGI N-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Year ended December 31, 2008/font/div /td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="4%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="3%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="92%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MAR GIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;% of total revenue/font/div /td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="4%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"13/font/td td nowrap="nowrap" valign="bottom" width="3%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"%/font/td /trtr bgcolor="white" td valign="bottom" width="92%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN - -RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;% of total accounts receivable at period end/font/div /td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="4%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"19/font/td td nowrap="nowrap" valign="bottom" width="3%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"%/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="92%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Year ended December 31, 2009/font/div /td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="4%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="3%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="92%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt " align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;% of total revenue/font/div /td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="4%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"14/font/td td nowrap="nowrap" valign="bottom" width="3%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"%/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="92%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;% of total accounts receivable at period end/font/div /td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="4%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"17/font/td td nowrap="nowrap" valign="bottom" width="3%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"%/font/td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block ; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Plan Sponsor revenue and accounts receivable is primarily in the Traditional Pharmacy Services segment with a lesser amount in the Specialty Pharmacy Services segment./font/div /div /div

PARENTHETICAL DATA TO CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2009	Dec. 31, 2008
Current assets
Receivables, less allowance for doubtful accounts	$ 11,504	$ 11,609
Stockholders' equity
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	42,766,478	41,622,629
Common stock, shares outstanding	39,675,865	38,691,356
Treasury stock, shares at cost	2,647,613	2,624,186

NOTE 5 - GOODWILL AND INTANGIBLES	12 Months Ended
NOTE 5 - GOODWILL AND INTANGIBLES	Dec. 31, 2009
Notes to Financial Statements [Abstract]
GOODWILL AND INTANGIBLES	div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"NOTE#160;5#160;#8212; GOODWILL AND INTANGIBLES/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company follows ASC 350 in accounting and reporting for its goodwill and intangible assets. ASC 350#160;states that goodwill is no longer subject to amortization over its estimated useful life. Goodwill is subject to at least an annual assessment for impairment by applying a fair-value based test.#160;#160;Management assesses im pairment in the fourth quarter of each year or whenever there is an impairment indicator.#160;#160;#160;The Company has two reporting units: Specialty Pharmacy Services and Traditional Pharmacy Services.#160;#160;#160;As of December 31, 2009 and 2008, all goodwill is associated with the Specialty Pharmacy Services reporting unit.#160;#160;Portions of goodwill are expected to be deductible for income tax purposes./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Based on its annual assessment for the year ended December 31, 2009, management determined that the fair value of the Company#8217;s Specialty Pharmacy Services reporting unit was greater than the carrying value of its net assets, and as such, no i mpairment was incurred for fiscal year 2009./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In 2008, the Company experienced a significant decline in its market capitalization below book value, which was sustained through the fourth quarter of 2008.#160;#160;The Company also previously announced changes in the status of long-term Specialty Pharmacy Services contracts.#160;#160;Those contract changes included (a) the decision by United Healthcare (#8220;UHC#8221;) to internalize services for HIV/AIDS and solid organ transplant drugs starting in the first quarter of 2009, and (b) the expiration of the Competitive Acquisition Program (#8220;CAP#8221;) with the Centers for Medicare and Medicaid Services effective December 31, 2008.#160;#160;The expiration or termination of these contracts, the reduced market capitalization of the Company and the reduced market capitalization of the Company#8217;s peers in the healthcare industry were considered to be potential indicators of impairment in contemplation of the Company#8217;s annual impairment analysis./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Based on its 2008 annual assessment, management determined that the fair value of the Company#8217;s Specialty Pharmacy Services segment was less than the carrying value of its net assets.#160;#160;The Company determined the fair value of the Specialty Pharmacy Services segment using a combination of an income approach using the discounted cash flow method and a market approach using the guideline public company method.#160;#160;The Company completed step two of the impairment analysis and concluded that the carrying value of the goodwill associated with the Specialty Pharmacy Services segment was impaired, resulting in a fourth quarter non-cash impairment charge of $90.0 million./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The following table provides a reconciliation of goodwill (in thousands):/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FO NT-FAMILY: Times New Roman"#160;/fontbr /#160;/div div align="left" table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Total/font/di v /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="88%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Balance as of December 31, 2007/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"114,824/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="88%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Goodwill acquired/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLA Y: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="88%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Goodwill adjustments/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE : 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(286/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td /trtr bgcolor="white" td valign="bottom" width="88%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMIL Y: times new roman"Goodwill impairment/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(90,040/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="88%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Balance as of December 31, 2008/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"24,498/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZ E: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="88%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Goodwill acquired/font/div /td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="88%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Goodwill adjustments/font/div /td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="b ottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="88%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Balance as of December 31, 2009/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font t;/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"24,498/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"As part of the 2008 annual assessment and in consideration of the impairment indicators, the Company also evaluated the recoverability of its property and equipment and definite-lived intangible assets in accordance with ASC 350.#160;#160;As a result, the Company determined that $3.9 million of definitive-lived intangible assets, consisting of $3.5 million of customer lists and $0.4 million of non-compete agreements, were impaired, and an impairment charge for this amount was recorded in the fourth quarter of 2008.#160;#160;These impairment tests were performed and the related impairment charges were recorded prior to completing the goodwill impairment analysis./font/div /div

NOTE 6 - PROPERTY AND EQUIPMENT	12 Months Ended
NOTE 6 - PROPERTY AND EQUIPMENT	Dec. 31, 2009
Notes to Financial Statements [Abstract]
PROPERTY AND EQUIPMENT	div div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"NOTE#160;6#160;#8212; PROPERTY AND EQUIPMENT/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Property and equipment, at cost, consists of the following at December#160;31 (in thousands):/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"#160; /div div align="left" table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2009/font/div /t d td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2008/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="76%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Computer and office equipment, including equipment acquired under capital leases/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"23,067/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"13,534/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="76%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Work in progress/font/div /td t;td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"971/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: rig ht"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"7,161/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="76%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Furniture and fixtures/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,998/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,760/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" #160;/font/td /trtr bgcolor="white" td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Leasehold improvements/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inl ine; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"9,818/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"8,418/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trt r bgcolor="#cceeff" td valign="bottom" width="76%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"36,854/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" s tyle="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"31,873/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Less: Accumulated depreciation/font/div /td td align="right" valign="bottom" width="1 %" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(21,400/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#16 0;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(17,125/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Property and equipment, net/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SI ZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"15,454/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style= "BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"14,748/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Work in progress for 2009 and 2008 includes $0.7 million and $5.7 million, respectively, of costs capitalized for internal use software./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Depreciation expense for the years ended December#160;31, 2009, 2008 and 2007 was $5.0#160;million, $4.5#160;million and $4.2#160;million, respectively.#160;#160;In 2009, $0.9 million of depreciation expense related to capitalized computer software costs for internal use was recorded.#160;#160;Previous to 2009 no significant cost of software developed for internal use was recorded to depreciation expense./font/div /div /div

NOTE 7 - LINE OF CREDIT	12 Months Ended
NOTE 7 - LINE OF CREDIT	Dec. 31, 2009
Notes to Financial Statements [Abstract]
LINE OF CREDIT	div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"NOTE 7#160;#8212; LINE OF CREDIT/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"At December 31, 2009, there was $30.4 million in outstanding borrowings under our revolving credit facility (the #8220;Facility#8221;) with an affiliate of Healthcare Finance Group, Inc. (#8220;HFG#8221;), as compared to $50.4 million at December 31, 2008.#160;#160;The Facility provides for borrowing up to $85.0 million at the London Inter-B ank Offered Rate (#8220;LIBOR#8221;) or a pre-determined minimum rate plus the applicable margin and other associated fees, provided a sufficient level of receivable assets are available as collateral.#160;#160;The term of the Facility runs through November 1, 2010.#160;#160;Under the terms of the Facility, the Company may request to increase the amount available for borrowing up to $100.0 million, and convert a portion of any outstanding borrowings from a Revolving Loan into a Term Loan.#160;#160;The borrowing base utilizes receivable balances and proceeds thereof as security under the Facility.#160;#160;At December 31, 2009 the Company had $54.6 million of credit available on a borrowing basis of $85.0 million under the Facility./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify" lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The weighted average interest rate on the line of credit was 4.4% during 2009 compared to 5.0% for 2008./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Facility contains various covenants that, among other things, require the Company to maintain certain financial ratios as defined in the agreements governing the Facility.#160;#160;In December 2009, the Company and HFG agreed to amend the terms of the Facility to revise certain calculations required by the covenants. The Company was in compliance with all the covenants contained in the agreements as of December 31, 2009./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt" ;br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"As part of the anticipated acquisition of CHS, the Company has received a financing commitment from Jefferies Finance LLC (#8220;Jefferies#8221;) to provide a five year senior credit facility in the amount of $150.0 million, including a $50.0 million revolver, and a $225.0 million bridge loan facility.#160;#160;The bridge loan facility will be drawn on only if the $225.0 million, five and a half year unsecured notes are not sold prior to the closing date of the acquisition.#160;#160;The Company plans to use $100.0 million of the senior term loan and the proceeds from the senior unsecured notes offering to finance, in part, the acquisition of CHS, to refinance its existing indebtedness and repay CHS#8217;s existing indebtedness, for general corporate p urposes and to pay related fees and expenses.#160;#160;The $50.0 million revolver is expected to be undrawn at closing.#160;#160;The specific interest rates of the senior term loan and notes is subject to final pricing and#160;the Company expects the interest to reflect market rates relative to its credit ratings.#160;#160;See Note 14 #8211; Subsequent Events for additional information about the proposed acquisition of CHS./font/div /div

NOTE 8 - COMMITMENTS AND CONTINGENCIES	12 Months Ended
NOTE 8 - COMMITMENTS AND CONTINGENCIES	Dec. 31, 2009
Notes to Financial Statements [Abstract]
COMMITMENTS AND CONTINGENCIES	div div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"NOTE#160;8#160;#8212; COMMITMENTS AND CONTINGENCIES/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Legal Proceedings/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"On February#160;14, 2005, a complaint was filed in the Alabama Circuit Court for Barbour County, captioned font style="DISPLAY: inline; FONT-STYLE: italic"Eufaula Drugs, Inc.#160;v. ScriptSolutions /font[sic], one of approximately fourteen substantially identical complaints commenced in Alabama courts against various unrelated pharmacy benefit management companies. On April#160;8, 2005, the plaintiff filed an amended complaint substituting BioScrip PBM Services f/k/a ScripSolutions (#8220;PBM Services#8221;) as the defendant, seeking unspecified money damages and injunctive relief, and alleging breach of contract and related tort and equitable claims on behalf of a putative nationwide class of pharmacies alleging insufficient reimbursement for prescriptions dispensed by ScripSolutions, principally on the theory that PBM Services was obligated to update its prescription pricing files on a daily rather than weekly basis . Following preliminary proceedings and class discovery, the parties reached a settlement agreement on August 6, 2009, in which the Company continues to deny liability, with a class of pharmacies which was certified solely for settlement purposes, and class members were entitled to receive $0.065 for each branded prescription filled during the settlement class period.#160;#160;The court approved the settlement on November 4, 2009 and a final judgment dismissing the action has been entered in the action, the time to appeal which has expired.#160;#160;The costs of the settlement are covered by insurance./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The sellers of a company, Northland Pharmacy, to Chronimed Holdings, Inc., ( now known as BioScrip Pharmacy, Inc.) one of BioScrip#8217;s subsidiaries, are claiming a right to additional purchase price of at least $5.64 million in connection with an earn out provision in the stock purchase agreement regarding the acquisition.#160;#160;The sellers, named DiCello, first sued in federal court in Ohio in July 2007, but the court stayed the case and directed arbitration of the disagreement by the accounting firm KPMG, LLP, as the stock purchase agreement provides.#160;#160;BioScrip Pharmacy denies owing the sellers any additional purchase price.#160;#160;The parties have made extensive filings as directed by the arbitrator and are waiting for either the arbitrator#8217;s decision or instructions as to further proceedings in the matter.#160;#160;The Company is confident in its position and does not believe an adverse ruling is likely; however, there can be no assurance that an adverse ruling will not be rendered.#160; #160;If the arbitrator rules in favor of DiCello, such ruling could have a material adverse effect on the Company#8217;s business, operations, or financial position./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Government Regulation/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Various Federal and state laws and regulations affecting the healthcare industry do or may impact the Company#8217;s current and planned operations, including, without limitation, Federal and state laws prohibiting kickbacks in government health programs, Federal and state antitrust and drug distribution laws, and a wide variety of consumer protection, insurance and other state laws and regulations. While management believes that the Company is in substantial compliance with all existing laws and regulations material to the operation of its business, such laws and regulations are subject to rapid change and often are uncertain in their application. As controversies continue to arise in the healthcare industry (for example, regarding the efforts of Plan Sponsors and pharmacy benefit managers to limit formularies, alter drug choice and establish limited networks of participating pharmacies), Federal and state regulation and enforcement priorities in this area can be expected to increase, the impact of which on the Company cannot be predicted. There can be no assurance that the Company will not be subject to scrutiny or challenge under one or more of these laws o r that any such challenge would not be successful. Any such challenge, whether or not successful, could have a material adverse effect upon the Company#8217;s financial position, results of operations and cash flows. Violation of the Federal anti-kickback statute, for example, may result in substantial criminal penalties, as well as suspension or exclusion from the Medicare and Medicaid programs. Further, there can be no assurance that the Company will be able to obtain or maintain any of the regulatory approvals that may be required to operate its business, and the failure to do so could have a material adverse effect on the Company#8217;s financial position, results of operations and cash flows./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT - -STYLE: italic; FONT-FAMILY: Times New Roman"Operating Leases/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company leases its facilities and certain equipment under various operating leases with third parties. Facility lease terms are generally five years, the majority containing options to extend for periods ranging from one to five years. Approximately 80% of these leases contain escalation clauses that increase base rent payments based upon either the Consumer Price Index or an agreed upon schedule. Equipment leases are generally for periods of three to five years./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEX T-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The future minimum lease payments under operating leases at December#160;31 are as follows (in thousands):/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"#160;/div div align="left" table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" tr bgcolor="#cceeff" td valign="bottom" width="88%" style="TEXT-ALIGN: left" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2010/f ont/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"4,738/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="88%" style="TEXT-ALIGN: left" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt ; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2011/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,489/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="88%" style="TEXT-ALIGN: left" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2012/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,784/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT - -SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="88%" style="TEXT-ALIGN: left" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2013/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,227/font gt;/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="88%" style="TEXT-ALIGN: left" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2014/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign=" bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,897/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td valign="bottom" width="88%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Thereafter/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width=" 1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"4,013/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td valign="bottom" width="88%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"19,148/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN- LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Rent expense for leased facilities and equipment was approximately $5.1 million, $4.6#160;million and $4.4#160;million for the years ended December#160;31, 2009, 2008 and 2007, respectively./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Security Interest and Letters of Credit/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FON T-FAMILY: Times New Roman"Under the terms of the prime vendor agreement with AmerisourceBergen Drug Company (#8220;ABDC#8221;), the Company granted ABDC a secured, first priority lien in all of its inventory as well as the proceeds thereof.#160;#160;In the ordinary course of business, the Company obtained certain letters of credit (#8220;LC#8221;) from commercial banks in favor of various parties.#160;#160;At December 31, 2009 there was $1.1 million on deposit as collateral for these LCs./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Purchase Commitments/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"As of December 31, 2009, the Company had commitments to purchase prescription drugs from drug manufacturers of approximately $17.7 million in 2010.#160;#160;These purchase commitments are made at levels expected to be used in the normal course of business./font/div /div /div

NOTE 10 - TREASURY STOCK	12 Months Ended
NOTE 10 - TREASURY STOCK	Dec. 31, 2009
Notes to Financial Statements [Abstract]
TREASURY STOCK	div div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"NOTE#160;10#160;#8212; TREASURY STOCK/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"On February#160;27, 2003, the Executive Committee of the Board of Directors (the #8220;Board#8221;) approved a stock repurchase program authorizing the Company to repurchase up to an aggregate of $10.0#160;million of its common stock in open market or private transactions. No stock was repurchased during 2009, 2008 or 2 007; however, during 2009, 2008 and 2007, 33,552; 187,544 and 189,492 shares, respectively, were surrendered to satisfy tax withholding obligations on the vesting of restricted stock awards. As of December#160;31, 2009, approximately $4.9#160;million of the $10.0#160;million authorized remains available for additional share repurchases. The Company holds a total of 2,647,613#160;shares of treasury stock acquired under current and prior repurchase programs as well as forfeitures to satisfy tax obligations in the vesting of restricted stock awards./font/div /div /div

NOTE 12 - DEFINED CONTRIBUTION PLAN	12 Months Ended
NOTE 12 - DEFINED CONTRIBUTION PLAN	Dec. 31, 2009
Notes to Financial Statements [Abstract]
DEFERRED COMPENSATION PLANS	div div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"NOTE#160;12#160;#8212; DEFERRED COMPENSATION PLANS/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company maintains a deferred compensation plan under Section#160;401(k) of the Internal Revenue Code. Under the Plan, employees may elect to defer up to 50% of their salary, subject to Internal Revenue Service limits. The Company may make a discretionary matching contribution. The Company recorded matching co ntributions in selling, general and administrative expenses of $1.1#160;million, $0.9#160;million and $1.0#160;million in the years ended December#160;31, 2009, 2008, and 2007, respectively./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In 2008 the Company entered into a deferred compensation agreement with its Chief Executive Officer to provide certain retirement benefits.#160;#160;These benefits are earned over the period of his employment contract.#160;#160;The Company recorded $0.5 million and $0.3 million of compensation expense for the years ended December 31, 2009 and 2008, respectively./font/div /div /div